This review focuses on the probable anti-cancer mechanisms of human amniotic membrane (AM) that may be very helpful for ongoing cancer research activities with AM. A thorough search was conducted on PubMed for any published literature on the anti-cancer role of human AM using the key words, e.g., AM, function of AM, angiogenesis prevention, apoptosis induction by AM. No particular exclusion criteria were set. We selected resources from 1960 to 2018 with special focus on articles published during the last 7 years that revealed information regarding AM-derived factors and their specific functions to prevent cancer. Many studies suggest that human AM-derived epithelial stem cells (AMhAECs) and mesenchymal stem cells (AM-hMSCs) secrete various factors, e.g., thrombospondin (TSP), tissue inhibitor metalloproteinase (TIMP), plasminogen activator inhibitors (PAI), IL-1 receptor antagonist (IL1RN), granulocyte monocyte-colony stimulating factor (GM-CSF), cytokines specially IL-6 and IL-10, various essential markers, and proteins which most predominantly increase the AM's anti-cancer activity. This work gives an overview of the latest findings on AM function and evaluates its potential use in cancer treatment. Though various researches are being performed now on the anti-neoplastic properties of AM, the mechanism of these effects is not clear yet. Therefore, it has a great demand to unveil the mood of action of AM as to exert anti-cancer activity. From the meta-analysis of previous data, this review has pointed out an anti-cancer mechanism of AM that would help to use it as an anti-cancer therapy.
Introduction
Malignancy, one of the major clinical concerns that affect humanity today, in fact, is the second deadliest disease after cardiovascular disease. According to the estimates of WHO, cancer mortality rates rise 9.6 million globally in 2008 (https:// www.who.int/news-room/fact-sheets/detail/cancer). Among various types of cancers, lung and breast cancer have the highest prevalence rate (2.09 million cases) (https://www. who.int/news-room/fact-sheets/detail/cancer). Besides, colorectal, prostate, stomach, and non-melanoma skin cancers are also predominant. According to the report of WHO, near about 1 in every 6 deaths occurs due to cancer and this mortality rate is higher in poor income countries (70% deaths). Unlike Europe (incidence rate 23.4%, mortality rate 20.3%) and America (incidence rate 21.0%), mortality rate 14.4%), the mortality rate due to cancer in Asia and Africa (57.3% and 7.3% respectively) is greater than their incidence rates (48.4% and 5.8% respectively) [1] .
In modern medical sector, conventional treatments to treat cancer are chemotherapy, radiotherapy, and surgery [2] . Failures of conventional treatment modules, including chemotherapy and radiation therapy, represent a magnitude of serious side effects [3] . Lately, the demand is increasing worldwide for safe and more effective therapeutic agents to treat cancer [4] . Several new ideas have emerged in the treatment of cancer among which the use of steam cell has been become the most outstanding aspects. Damage of the blood and immune system due to the invasion of cancer cells or the side effect of both chemotherapy and radiotherapy has been controlled and treated by using stem cells [5] . Many performed studies suggest the AM-derived stem cells to be used as cancer gene therapy through stem cell transplantation due to their significant roles [6] [7] [8] . Since, amniotic membrane (AM) has anti-cancer properties, researchers are thinking about its therapeutic uses in cancer treatment. So, to discover its anti-cancer mechanism has become a great target and focus to the researchers in the present era [9] .
Amniotic Membrane, Its Structure and Composition
AM is the inner thin layer of fetal placenta which covers the amniotic fluid and it has no nerves, muscles, and even the blood vessels [10, 11] . It is around 0.02 to 0. 5 mm in thickness and consists of three major layers, namely (i) the epithelial layer, (ii) the basement membrane, and (iii) the mesenchymal layer [12] [13] [14] [15] [16] [17] [18] . The layers contain various proteins including collagen I, II and V, CA125, oxytocin receptors [16, 19] , (desmin, actin, α-actinin, vimentin, tubulin, spectrin, cytokeratins), junctional proteins (desmoplakin, claudin, occuldin), and proteoglycans, hyaluronan, collagens which play important role in maintenance of human health [20] [21] [22] [23] [24] .
Clinical Application of AM
AM is being clinically used throughout the world due to the following properties.
1. Wound adherence properties [25] 2. No rejection phenomenon [26, 27] 3. Antimicrobial properties [26] [27] [28] [29] [30] [31] [32] [33] 4. Anti-scarring [34] 5. Minimizing fluid/water loss [24, 35, 36] 6. Pain reduction [29, [36] [37] [38] [39] [40] [41] [42] [43] 7. Less frequent dressing and faster wound healing [29, 34, 39, 44 , 45] 8. Neovascularization [41, 46, 47] Anti-cancer Mechanisms Exerted by AM
Prevention of Angiogenesis
AM synthesizes a number of anti-angiogenic proteins. Roles of these proteins in angiogenesis prevention are described here.
a. Collagen VIII Collagen VIII is a type of heparan sulfate proteoglycan and an important determinant of angiogenesis and tissue remodeling [32, 33] . Amnion epithelial and mesenchymal cells release collagen VIII which produces endostatin upon hydrolysis, a 20 kDa C-terminal protein of collagen VIII fragment [34] . Endostatin, as a broad-spectrum angiogenesis inhibitor, hinders the pro-angiogenic function of some growth factors especially VGEF and bFGF/FGF-2 [35] . Treatment with this collagen fragment has successfully prevented angiogenesis and inhibited liver malignancy [34] .
AM secrets a matrix protein called thrombospondin-1 that is multifunctional in nature and contains anti-angiogenic activity [33] . TSP-1 restricts migration of endothelial cells and triggers apoptosis. Thus, TSP-1 can directly inhibit angiogenesis. Additionally, TSP-1 possesses capability to prevent angiogenesis indirectly as well. It accomplishes this action by restricting the mobility of pro-angiogenetic factors and limiting their interactions with the receptors on endothelial cell surface [36] .
c. Tissue Inhibitors of Metalloproteinases (TIMPs)
AM-derived epithelial stem cell produces tissue inhibitors of metalloproteinases (TIMPs) that have the ability to contribute to the inhibition of angiogenesis and tumor development [38] . TIMP family consists of four different types of protease inhibitors such as TIMP-1, TIMP-2, TIMP-3, and TIMP-4. All the TIMPs have in-built ability to impede the function of matrix metalloproteinases (MMPs). MMPs take part in the degradation of extracellular matrix [39] . Therefore, they can facilitate angiogenesis by assisting the tumor cells to invade the basal lamina. Among the TIMP family members, TIMP-2 has an additional function of directly suppressing multiplication of endothelial cells. Hence, it can prevent angiogenesis not only by inhibiting protease activity of extracellular matrix but also by suppressing proliferation of quiescent tissues upon stimulated by signaling molecules.
d. Plasminogen activator inhibitor (PAI)
Plasminogen activator inhibitors PAI-1 and PAI-2 released by both AM-derived epithelial and mesenchymal cells can inhibit angiogenesis. PAI-1 suppresses the functions of MMPs, which helps the malignant cells to invade the basal lamina. It functions to inhibit formation of plasmin from plasminogen so that it cannot degrade the extracellular matrix [40] . The other plasminogen activator inhibitor, PAI-2, plays a similar role to prevent angiogenesis [41] .
e. Interleukin-10 (IL-10) IL-10 secreted by AM directly blocks angiogenesis by inhibiting the secretion of MMP-2 and MMP-9. IL-10 is also shown to promote secretion of TIMP-1 [36] .
f. Interleukin-1 receptor antagonist (IL1RN) IL-1 can favor malignancy by inducing expression of some potent angiogenic factors like VEGF and IL-8 [42, 43, 45, 47] . Interleukin-1 receptor antagonist (IL1RN), as suggested by its name can antagonize the cancer promoting activity of IL-1. Through obstructing the transcriptional impact of IL-1 on cyclooxygenase-2, which apparently plays a significant job in tumor advancement, enhanced expression of IL1RN does not allow skin carcinoma cells to develop malignancy [46] . It has likewise been accounted for that IL1RN itself had antiangiogenic impacts in tumors. It diminishes the expression of angiogenic factors, e.g., VEGF and IL-8 [47] . Figure 1 shows the anti-angiogenic mechanism of AM to prevent cancer and the anti-angiogenic factors secreted by AM and their respective roles in angiogenesis prevention are listed in Table 1 .
Role in Cell Cycle Arrest
It is known that the multiplication of cancer cells is dependent on cell cycle [48] . Whether cells will proceed to complete the cycle or remain arrested is regulated at certain checkpoints of the cell cycle. If the damage is not repaired, cells cannot proceed the checkpoints and remain arrested. If those check points fail and damaged cells survive, cancer cells arise. Along these lines, reclamation of the cell cycle checkpoints or blocking cancer cells in the G1 stage will check the growth of the tumor [49] . A study with mesenchymal cells with AM (hMSCs) on different cancer cell lines showed that it could arrest the cancer cells at G0/G1 phase and did not let them to enter the S phase [14] . It has been found that a number of soluble anti-proliferative factors and cytokines, e.g., GM-CSF (granulocyte macrophage-colony stimulating f a c t o r ) , I L -6 ( i n t e r l e u k i n -6 ) , I F N -α , and -β (interferon-α and -β), are constitutively secreted by hMSCs [49] .
Downregulating the Positive Regulators
Some factors released by hMSCs can negatively affect the expression of cancer cell genes that are necessary for G0/G1 phase transition and for S phase and DNA synthesis. From previous studies, cyclins (cyclin D2, E1, H), cyclin-dependent kinases (CDK 2, 4, 6), proliferating cell nuclear antigens (PCNA), and minichromosome maintenance complex (MCM 2,4,5) etc. are found to be some noteworthy examples of such affected regulators [14] . 
Upregulating the Negative Regulators
Negative impact on aforementioned positive mediators is joined by the upregulation of negative mediators of cell cycle as well. Previous researches showed that those upregulated factors include the CDK inhibitor 1A (CDKN1A or p21) and CDKN2B p15 and p27 [50, 51] . Cullin-1 (CUL1) participates in degrading several vital proteins, including p21 [52] . In this manner, downregulating CUL1 might also play role in cell cycle arrest. Moreover, cyclin G2, an unconventional cyclin, is upregulated whose expression is associated with cell cycle arrest and inhibition [53, 54] . A different study showed that the expression of retinoblastoma protein (pRB) is upregulated, an important event for proper cell cycle arrest in G0/G1 phase. Whereas, RB-like 1 (p107), whose levels are generally low in quiescent cells and high when cells proliferate, is downregulated (Table 2 ) [55] . The whole cell cycle arrest mechanism played by AM is shown in Fig. 2 .
Induction of Apoptosis in Cancer Cells

Inhibition of HSP90
HSP is an ATP-dependent molecular chaperon which facilitates proper protein folding and inhibits accumulation of misfolded proteins. HSPs family is classified on the basis of their member's molecular sizes, including HSP100, HSP90, HSP70, HSP60, HSP40, and small heat shock protein which plays vital role in tumorigenesis. HSPs facilitate activation of numerous oncogenic proteins in cancer cells [56, 57] . Among these proteins, HSP90 plays vital roles in malignancies [58] . Hence, HSP90 function has provided an attractive target in cancer treatment. Inhibiting HSP90 in vivo and in vitro has been proved an efficient way to antagonize cancer in prostate, pancreas, and lung neoplasms [59] [60] [61] . Clinical trials on HSP90 inhibition in advanced and refractory solid tumors [62] [63] [64] and bone marrow malignancies [65, 66] have been successfully performed. Moreover, HSP90 activates NF-KB and hence can prevent apoptotic response. Death domain kinase RIP, as a HSP90-associated kinase, leads to cell protection against apoptotic death by allowing activation of NF-KB [67] . Studies also showed that HSP90 binds to APAF-1 (apoptotic protease activating factor-1) and prevents its cytochrome c-induced oligomerization and thus inhibits apoptotic process [68] . Mitochondria-released cytochrome-c leads to formation of AFAP-1-caspase-9 apoptosome which activates caspase cascade and triggers apoptosis. APAF-1 inhibition by HSP90 prevents apoptosis by blocking procaspase 9 activation [69] .
Bcl-2/Caspase Pathway
Another propounded mechanism of AM to induce apoptosis in cancer cells is via Bcl-2/caspase pathway. In this pathway, the Bcl-2 family which includes apoptosis inhibiting as well as apoptosis-accelerating gene products (e.g., Bcl-2 and Bax respectively) triggers apoptotic response [69] [70] [71] . The ratio between apoptosis-accelerating proteins and apoptosis-inhibiting proteins such as Bax and Bcl-2, respectively controls the vulnerability of tumor cells in inducing apoptosis. Previous researches assert that Bax takes part in apoptotic cell death [72, 73] . In another study, treatment of glioma cells with amniotic membrane has increased the expression of apoptotic markers, e.g., Bax, caspase 8, and caspase-3 and decreased Bcl-2 expression. Hence, their growth was inhibited [13] . Therefore, the decreased ratio of Bcl-2/Bax is responsible for triggering apoptosis in glioma cells. Such circumstances turned the downstream caspase-8 and caspases-3 genes on and initiated an apoptosis. The ultimate mechanism of cancer cells apoptosis by AM is shown in Fig. 3 .
Discussion
Despite pursuing the true fact that the malignant form of cancer leads to certain death, the researchers from all over the world cannot find out the exact solution how to get rid of it. To combat cancer, lately, the use of AM has attracted much attention of researchers because of its unique properties. Scientists have unrevealed various anti-tumorigenic properties such as anti-angiogenic, immunoregulatory, and pro-apoptotic activities [74] [75] [76] [77] [78] [79] [80] [81] [82] . The cells most importantly amniotic epithelial and mesenchymal cells can play vital [36] . Besides, another study suggests that PEDF is a newly identified anti-angiogenic factor isolated from AM [74] . AM has the least chance to be rejected by the immune systems and the epithelial cells of it do not express HLA-A, HLA-B, HLA-C, and HLA-DR antigens [80] . During transplantation, some of the AM cells act as apoptotic cells and spontaneously vanish under certain condition [84] . An experiments with amniotic epithelial cells detected Fas-positive cells and apoptotic cells by immunohistochemistry and the TUNEL methods respectively [85] . AM stimulates the apoptosis of interferon-gamma-activated macrophages which is impossible for NO and TNF-γ [81] . However, various studies suggest the AM to have anti-cancer properties but the anti-tumorigenic mechanism of AM is yet abstruse and unclear. This review might help the researchers to comprehend and gather knowledge about the anti-cancer mechanism of AM which is badly needed for its clinical application in case of cancer therapy.
Conclusion and Future Direction
To be used as a cancer therapeutic agent in the clinical level, the first and most crucial object is to elucidate the exact anticancer mechanism of AM. In this review, the most presumable mechanism of AM in its anti-cancer roles are described getting information from the previous studies that will be effective to find out a proper solution to treat cancer. Since AM is available, cost-effective, non-immunogenic, and possesses a large number of anti-cancer properties that exert specific functions to their target points and ultimately suppresses tumor, it may have a potential therapeutic to treat cancer.
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